PORT ST. LUCIE, Fla.--(BUSINESS WIRE)--The Vaccine and Gene Therapy Institute of Florida (VGTI-FL) has entered into a three-year research collaboration with Merck, known as MSD outside the United States and Canada, in the field of HIV latency. The collaboration is designed to foster public-private partnerships to accelerate progress toward an HIV cure. Under the collaboration, investigators from both institutions will develop novel methods to characterize potential latency candidates, discover and validate targets and pathways that could facilitate the elimination of latently infected cells, and identify biomarkers that would be predictive of HIV eradication in vivo.
